24/12/2025
On ESMO Asia Day 1, Dr Joline had the privilege of chairing the ESMO satellite symposium on navigating treatment for HR+ HER2- metastatic breast cancer🎗️. The rapid expansion of biomarker-driven therapeutic options in recent years has been remarkable, and learning from our APAC colleagues in Australia and Taiwan about best practices for testing and treatment sequencing was truly inspiring🌏💡.
Dr Choo also had the honor of chairing and moderating this year’s ESMO Women for Oncology (W4O) Forum alongside Dr Janice Tsang from Hong Kong👩⚕️👩⚕️. They were joined by inspiring colleagues from Spain, New Zealand, Bangladesh, and Singapore for a meaningful discussion on supporting women in oncology to build equitable, fulfilling, and successful careers💪✨. The panel’s personal anecdotes—honest, vulnerable, and powerful—resonated deeply with the room❤️. Their voices reminded us why this work matters and why the mission of W4O continues to be so important. It was truly heartening to see young female oncologists step forward, speak up, and ask thoughtful questions👏. More information on the ESMO W4O committee’s mission can be found here: https://www.esmo.org/career-development/women-for-oncology
Curie also had the honor of being involved in two studies selected for poster presentations📄🔬: one led by Dr Choo on functional drug sensitivity testing in refractory GI cancers, and another on the real-world use of zolbetuximab in gastric cancers in collaboration with NCCS.
